GSK (GLAXF) Common Stock

: $1,706 Mil (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

GSK's quarterly common stock declined from Jun. 2023 ($1,702 Mil) to Sep. 2023 ($1,668 Mil) but then increased from Sep. 2023 ($1,668 Mil) to Dec. 2023 ($1,706 Mil).

GSK's annual common stock declined from Dec. 2021 ($1,791 Mil) to Dec. 2022 ($1,641 Mil) but then increased from Dec. 2022 ($1,641 Mil) to Dec. 2023 ($1,706 Mil).

GSK Common Stock Historical Data

The historical data trend for GSK's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GSK Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

1,764.09

1,809.14

1,791.22

1,640.68

1,706.33

GSK Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Common Stock																1,640.68	1,635.92	1,702.02	1,668.32	1,706.33

GSK Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

GSK (GLAXF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GSK PLC (OTCPK:GLAXF) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

GSK:USA GSK N:Mexico GSKl:UK GSK:UK GS71:Germany GS70:Germany GS71:Germany GS70:Germany GS71:Germany G1SK34:Brazil GSK:Argentina

Address

980 Great West Road, Brentford, Middlesex, GBR, TW8 9GS

Website

https://www.gsk.com

In the pharmaceutical industry, GSK ranks as one of the largest companies by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.